[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-ventricular-hypertrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-ventricular-hypertrophy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,49,74,95,121,147,171,233,253,284,313,337,362],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100633682","ai-based-echocardiography-for-detection-of-cardiac-amyloidosis-100633682",false,"NCT07529860","AI-based Echocardiography for Detection of Cardiac Amyloidosis","AI-based Echocardiography for Detection of Cardiac Amyloidosis in Patients Undergoing Transthoracic Echocardiography With Left Ventricular Hypertrophy","ORCHESTRA","Inclusion Criteria:\n\n* Patients 18 years old or older\n* Left ventricular hypertrophy defined by a wall thickness of at least 12 mm\n* Echocardiographic red flags of suspected cardiac amyloidosis\n* Informed consent signed\n\nExclusion Criteria:\n\n* Patients with poor echocardiographic acoustic window to allow proper analysis of the data\n* Patients with known cardiac amyloidosis.","ALL","18 Years","95 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Cardiac amyloidosis is characterized by deposition of misfolded protein in the myocardium causing mainly heart failure symptoms with preserved left ventricular ejection fraction. There are also specific clinical (bilateral carpal tunnel syndrome, polyneuropathy, skin bruising, ruptured biceps tendon…), biomarkers (disproportionally elevated NT-proBNP to the degree of heart failure, persistent elevated troponin, proteinuria..), electrocardiographic (reduced voltage of QRS, atrial fibrillation..) and echocardiographic features (concentric left ventricular hypertrophy, dilated atria, reduced global longitudinal strain with typical pattern of apical sparing, diastolic dysfunction…). Early diagnosis of the disease is crucial to identify patients that may benefit from appropriate treatment. Suspected cardiac amyloidosis on echocardiography or on cardiac magnetic resonance needs to prompt the request of serum free-light chain quantification and serum and urine immunofixation as well as single photon emission computed tomography (SPECT) using bone radiotracers. Echocardiography is the imaging technique of first choice to evaluate patients with dyspnea complaints and suspected heart failure as well as other pathologies. Echocardiography is a technique of first choice to evaluate patients with cardiovascular risk factors such as arterial hypertension and diabetes and many of those patients may have echocardiographic features that can be observed in early phases of cardiac amyloidosis. Currently, identification of patients with cardiac amyloidosis with available echocardiographic tools remains challenging. However, novel artificial intelligence (AI)-based algorithms applied to echocardiographic images for analysis may help the cardiologists in the identification of early phase of cardiac amyloidosis. Early diagnosis of cardiac amyloidosis is key to implement effective therapies that have demonstrated to improve survival. Several studies have demonstrated the accuracy of AI-based algorithms applied to echocardiography for the diagnosis of cardiac amyloidosis. The hypothesis of the present prospective study is to evaluate the accuracy of the AI-based algorithm to identify patients with echocardiographic findings suggestive of cardiac ATTR amyloidosis using as ground truth the subsequent analysis with imaging techniques that permit its diagnosis such as 99mTc-pyrophosphate (PYP) SPECT and cardiac magnetic resonance as well as hematologic tests. If needed, histological confirmation on cardiac or extracardiac tissue could be performed, as recommended by recent consensus document from the Heart Failure Association of the European Society of Cardiology.\n\nIn addition, this study will help to answer the true prevalence of ATTR cardiac amyloidosis among patients referred to transthoracic echocardiography that present red flags for ATTR cardiac amyloidosis. The AI-based algorithm is the software Us2.ai which has been used in other populations for this purpose, as previously published.",[28,29,30],"Cardiac Amyloidosis","Heart Failure With Preserved Ejection Fraction (HFPEF)","Left Ventricular Hypertrophy",[32,33,34,35,36],"artifical intelligence","echocardiography","strain","cardiac amyloidosis","left ventricular hypertrophy","NOT_YET_RECRUITING","2026-06-10",{"date":40,"type":41},"2026-06-12","ACTUAL",{"date":43,"type":22},"2026-07-01",{"date":45,"type":22},"2028-10",{"name":47,"class":48},"Germans Trias i Pujol Hospital","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100484822","phase-4-mineralocorticoid-receptor-coronary-microvascular-function-and-cardiac-efficiency-in-hypertension-100484822","NCT05593055","Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension","Inclusion Criteria:\n\n1. History of hypertension\n\n   1. Seated systolic BP \\\u003C 180 mmHg and diastolic \\\u003C 110 mmHg if on antihypertensives\n   2. Seated systolic BP 141-200 mmHg and\u002For diastolic BP 90-114 mmHg if not on antihypertensives\n2. LVH by echocardiogram\n\n   1. For men: interventricular septum thickness ≥ 12mm\n   2. For women: interventricular septum thickness ≥ 11mm\n3. We will also allow inclusion of people with treated hypothyroidism, pre-diabetes and diabetes controlled by diet, exercise, and\u002For metformin.\n\nExclusion Criteria:\n\n* Use of MR antagonist (eplerenone, spironolactone, or finerenone) or amiloride (amiloride inhibits ENaC, which is a key mediator of MR's actions) within the past year\n* Orthostatic hypotension\n* Major medical illness, including uncontrolled diabetes mellitus (Hemoglobin A1c \\>7.5)\n* LV ejection fraction \\\u003C 40%\n* New York Heart Association class III to IV congestive heart failure or unstable angina\n* A history in the prior 6 months of Q-wave myocardial infarction, stroke, transient ischemic attack, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft\n* History of secondary hypertension\n* Known genetic cardiomyopathy\n* Renal disease (seum creatinine \\>1.5 mg\u002FdL for men and \\>1.3 mg\u002FdL for women)\n* Hepatic disease\n* Bronchospastic lung disease\n* Alcohol or substance abuse\n* Hormone replacement therapy\n* Abnormal values for electrolytes, liver enzymes or TSH\n* Pregnancy or lactation\n* All individuals \\\u003C18 and \\>75 years will be excluded due to safety concerns of administering an angiotensin-II infusion in these patient groups.","75 Years",{"count":57,"type":22},75,[59],"PHASE4","The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).",[62,30],"Hypertension","RECRUITING","2026-04-03",{"date":66,"type":41},"2026-04-06",{"date":68,"type":41},"2023-08-25",{"date":70,"type":22},"2027-12-31",{"name":72,"class":48},"Brigham and Women's Hospital",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100622228","left-ventricular-hypertrophy-in-ckd-patients-100622228","NCT07380893","Left Ventricular Hypertrophy in CKD Patients","Prevalence of Left Ventricular Hypertrophy (LVH) in CKD Patients and Effect of Erythropoietin Therapy","Inclusion Criteria:\n\n* Adults (≥18 years) diagnosed with CKD stages 3-5.\n* Stable clinical condition for ≥3 months.\n* Anemia (Hb \\\u003C10 g\u002FdL) for cohort phase.\n* Willingness to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Valvular or ischemic heart disease.\n* Uncontrolled hypertension (BP \\>180\u002F110 mmHg).\n* Acute coronary syndrome or decompensated heart failure in the past 3 months.\n* Malignancy or active infection",{"count":82,"type":22},100,"OBSERVATIONAL","The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.\n\nThe main question it aims to answer is:\n\nDoes erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?",[30],"2026-01-24",{"date":88,"type":41},"2026-02-02",{"date":90,"type":22},"2026-01-15",{"date":92,"type":22},"2026-07-15",{"name":94,"class":48},"Sohag University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":73},"100597694","evaluation-of-left-ventricular-ejection-fraction-using-an-accelerated-cardiac-cine-mri-sequence-with-deep-learning-based-image-reconstructions-100597694","NCT07061821","Evaluation of Left Ventricular Ejection Fraction Using an Accelerated Cardiac Cine-MRI Sequence With Deep Learning-based Image Reconstructions","Evaluation of Left Ventricular Ejection Fraction Using an Accelerated Cardiac Cine-MRI Sequence With Deep Learning-based Image Reconstructions Compared to the Reference Cine-MRI Sequence in the Assessment or Follow-up of Left Ventricular Hypertrophy","HVGLD","Inclusion Criteria:\n\n* Patient referred for cardiac MRI as part of the assessment or follow-up of left ventricular hypertrophy\n* Age ≥ 18 years old\n* Ability of the subject to understand and express his consent\n* Affiliation to the social security scheme\n\nExclusion Criteria:\n\n* Severe obesity (\\>140 kg) preventing the patient from entering the scanner bore, which has a diameter of less than 70 cm\n* Age ≥ 18 years old\n* Person under guardianship or curators, or deprived of liberty\n* Pregnant or breastfeeding woman\n* Known allergy to gadolinium chelates\n* Claustrophobia\n* Any contraindication to MRI\n* Arrhythmia\n* Inability to hold breath for more than 10 seconds",{"count":104,"type":22},61,[25],"Left ventricular hypertrophy (LVH) is a common condition that may result from hypertension, hypertrophic cardiomyopathy, aortic valve stenosis, or certain metabolic disorders. Cardiac imaging is essential for diagnosis, prognostic assessment, and quantification of cardiac function. While transthoracic echocardiography remains widely used, it is limited by acoustic window dependence and inter-observer variability. Cardiovascular Magnetic Resonance (CMR) imaging currently serves as the reference standard for measuring left ventricular ejection fraction (LVEF), cardiac volumes, and tissue characterization. However, conventional cine-CMR sequences require repeated breath-holds, which are often challenging for elderly or dyspneic patients, generating respiratory motion artifacts that compromise image quality. Accelerated cine-CMR sequences with deep learning-based image reconstructions offer a promising alternative by significantly reducing acquisition time while preserving image quality. This study aims to evaluate whether these accelerated cine-CMR sequences provide LVEF measurements concordant with conventional cine-CMR sequences, with potential to improve patient comfort and reduce examination time.",[108,109,110,111,30],"Left Ventricular Ejection Fraction","Cardiac Magnetic Resonance Imaging","Deep Learning","Image Reconstruction",[30,108,109,110,111],{"date":114,"type":41},"2026-01-16",{"date":116,"type":41},"2025-08-05",{"date":118,"type":22},"2026-09",{"name":120,"class":48},"Centre Hospitalier Universitaire, Amiens",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":73},"100327931","imaging-histone-deacetylase-in-the-heart-100327931","NCT03549559","Imaging Histone Deacetylase in the Heart","Imaging of Histone Deacetylase in the Heart","Inclusion Criteria:\n\nGroup 1: Healthy Volunteers (n = 30)\n\n* Healthy adults with no known history of medical disease\n* Age 18-85 years\n* No history cardiovascular disease\n* Ability to provide informed consent\n\nGroup 2: Patients with Diabetes (n = 16)\n\n* Age 18-85 years\n* Diagnosis of diabetes\n* Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction\n* Ability to provide informed consent\n\nGroup 3: Patients with Aortic Stenosis (n = 50)\n\n* Age 18-85 years\n* Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Known contraindication to MRI",true,"85 Years",{"count":131,"type":22},96,[25],"The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.",[135,30,136,137],"Heart Failure With Normal Ejection Fraction","Aortic Valve Stenosis","Diabetes","2025-12-18",{"date":140,"type":41},"2025-12-22",{"date":142,"type":41},"2018-09-07",{"date":144,"type":22},"2026-09-01",{"name":146,"class":48},"Massachusetts General Hospital",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":128,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":73},"100283749","early-phase-1-diffusion-mri-in-heart-failure-100283749","NCT02973633","Diffusion MRI in Heart Failure","Inclusion Criteria:\n\n* Healthy adults with no history of hypertension, diabetes or heart disease\n* Patients with ST Elevation MI within last 6-10 weeks who are angina free, and have been seen by a cardiologist since discharge\n* Patients with episode of heart failure within last 12 months and left ventricular hypertrophy, documented by echocardiogram or MRI.\n\nExclusion Criteria:\n\n1. Presence of metallic foreign bodies\u002Fobjects\n2. Selected medical devices and implants\n3. Pacemakers, implantable defibrillators, life vests\n4. Coronary artery stent within last 6 weeks (unless the stent is a MRI-inert chromium-cobalt stent)\n5. Known untreated ventricular arrhythmia such as sustained ventricular tachycardia within last 12 months\n6. Atrial fibrillation that is not well rate controlled (heart rate \\>125)\n7. Unstable angina within last 2 months that has not been fully evaluated by a cardiologist\n8. Syncope within last 6 weeks\n9. Hemodynamic instability (Systolic BP less than 100 or greater than 180)\n10. Decompensated heart failure (inability to lie flat and perform a breath-hold).\n11. Glomerular filtration rate (GFR) \\\u003C 60 for those receiving gadolinium.\n12. Labile GFR that is not stable\u002Fsimilar on last 2 measurements (for those receiving gadolinium).\n13. Patients with GFR \\\u003C 20 or on any form of dialysis.\n14. Infiltrative cardiomyopathy (amyloid, sarcoid, hemachromatosis)\n15. Recent surgery (within the last 3 months)\n16. Prior stroke with large residual deficit\n17. Presence of liver or respiratory failure\n18. Pregnancy and nursing mothers\n19. Claustrophobia\n20. Known seizure disorder",{"count":154,"type":22},160,[156],"EARLY_PHASE1","The development of symptomatic heart failure is frequently preceded by a pre-clinical period of structural remodeling in the heart. The remodeling process driving this transition, however, remains poorly understood. The investigators hypothesize that imaging the diffusion of water in the heart with MRI will allow its microstructure to be resolved. The investigators further hypothesize that the characterization of microstructural changes in the heart will help elucidate the pathogenesis of heart failure and the transition from a compensated to a decompensated state. Patients with recent myocardial infarcts and left ventricular hypertrophy, who are at risk for the development of heart failure, will be enrolled. The participants will undergo serial diffusion tensor MRI (DTI) imaging of the heart to characterize changes in myocardial microstructure over time.",[159,160,30],"Heart Failure","Myocardial Infarction",[159,162,160,30,163],"Remodeling","Diffusion Tensor MRI",{"date":165,"type":41},"2025-12-24",{"date":167,"type":41},"2017-06-30",{"date":169,"type":22},"2028-12-31",{"name":146,"class":48},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":128,"sex":17,"minAge":179,"maxAge":18,"enrollmentInfo":180,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":182,"conditions":183,"keywords":200,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":73},"100420250","pediatric-hypertension-and-the-renin-angiotensin-system-phrase-100420250","NCT04752293","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage","PHRASE","INCLUSION CRITERIA: HYPERTENSION COHORT\n\n* 7-18 years of age at time of enrollment\n* Confirmed new diagnosis of primary hypertension: no identifiable secondary cause, referred to hypertension or nephrology clinic\n\n  * Age \\\u003C13 years: BP ≥95th %ile or ≥130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥130\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: HYPERTENSION COHORT\n\n* \\\u003C7 years or \\>18 years of age at time of enrollment\n* BP confirmed as normal or in the elevated BP category based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C95th %ile or \\\u003C130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C130\u002F80 mmHg\n* A confirmed secondary cause of hypertension\n* Confounding medical condition (heart or kidney disease \\[except hypertension-associated heart changes on echocardiogram or albuminuria\\], vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State\n\nINCLUSION CRITERIA: CONTROL COHORT\n\n* 7-18 years of age at time of enrollment\n* Normal BP based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C90th %ile or \\\u003C120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C120\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: CONTROL COHORT\n\n* \\\u003C7 or \\>18 years of age at time of enrollment\n* Elevated BP or hypertension, based on ≥3 prior office BP measurements on separate days:\n\n  * Age \\\u003C13 years: BP ≥90th %ile or ≥120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥120\u002F80 mmHg\n* History of elevated BP or hypertension\n* Current use of BP-lowering medications\n* Confounding medical condition (heart or kidney disease, vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State","7 Years",{"count":181,"type":22},125,"Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.",[62,30,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199],"Left Ventricular Dysfunction","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Diseases","Kidney Injury","Kidney Dysfunction","Sodium Urine High","Blood Pressure Disorders","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Proteinuria","Albuminuria",[201,202,62,203,204,30,199,205,206,207,208,209,210,211,212,213,214,215,216,217,186,188,218,219,197,220,221,222,223],"High Blood Pressure","Elevated Blood Pressure","Pediatric Hypertension","Target Organ Damage","Uric Acid","Klotho","Fibroblast Growth Factor 23","Renin-Angiotensin-Aldosterone System","Renin-Angiotensin System","Angiotensin-(1-7)","Angiotensin II","Angiotensin-Converting Enzyme 2","Angiotensin-Converting Enzyme","Causal Inference","Causal Mediation Analysis","Sensitivity Analysis","Predictive Analysis","Heart Rate Variability","Sodium","Lifecourse","Kidney Function","Ambulatory Blood Pressure Monitoring","Echocardiogram","2025-12-04",{"date":226,"type":41},"2025-12-11",{"date":228,"type":41},"2021-05-19",{"date":230,"type":22},"2026-12",{"name":232,"class":48},"Wake Forest University Health Sciences",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":128,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":73},"100613178","ai-enabled-diagnosis-and-prognosis-of-hypertrophic-cardiomyopathy-100613178","NCT07263204","AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy","Precision Diagnosis and Prognostic Prediction of Hypertrophic Cardiomyopathy Using Artificial Intelligence: A Multicenter Study","Inclusion Criteria:\n\n1. Adults aged ≥ 18 years.\n2. HCM cohort: Adults diagnosed with hypertrophic cardiomyopathy in accordance with the \\*2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults\\*.\n3. HCM phenocopy cohort: Adults with an LV wall thickness ≥ 13 mm at any site on echocardiography.\n4. Healthy-control cohort: Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography.\n\nExclusion Criteria:\n\nPatients from whom analyzable ECG data cannot be obtained.",{"count":241,"type":22},15000,"By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.",[244,30],"Hypertrophic Cardiomyopathy (HCM)","2025-11-23",{"date":224,"type":41},{"date":248,"type":41},"2025-01-01",{"date":250,"type":22},"2026-12-31",{"name":252,"class":48},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":128,"sex":17,"minAge":261,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":264,"conditions":265,"keywords":269,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":283},"100609525","us-benchmarking-clinical-study-100609525","NCT07215715","US Benchmarking Clinical Study","Myocardial & Hepatic Shear Wave Velocity Measurements in Patients With Non-Reduced-Ejection Fraction Heart Failure and Control Subjects - US Benchmarking Clinical Study","EMS-CT-1","Inclusion Criteria:\n\nInclusion Criteria Common to all three Study Arms:\n\n1. Male or female age ≥ 60 years\n2. Signed informed consent and able to comply with protocol\n\n   Inclusion Criteria Common to the Heart Failure with non-reduced left ventricular ejection fraction (LVEF) with or without transthyretin amyloid cardiomyopathy (ATTR-CM) Arms:\n3. Patients meeting the Universal Definition of Heart Failure \\& HeartShare study criteria.\n4. LVEF \\>40% on the last available imaging study\n5. Left ventricular hypertrophy (LVH) defined as left ventricular mass index (mass\u002FBSA) in female \\> 95 g\u002Fm², in male \\> 115 g\u002Fm² according to American Society of Echocardiography\u002FEuropean Association of Cariology (ASE\u002FEAC) guidelines42 OR as interventricular septum (IVS) thickness ≥12 mm\n\n   Inclusion criterion specific to HF with non-reduced LVEF without ATTR-CM Arm:\n6. Negative (grade 0) Pyrophosphate (PYP) scintigraphy within 24 months prior to the enrolment in the study OR Simple Score \\\u003C643 OR negative endomyocardial biopsy\n\n   Inclusion criterion specific to HF with non-reduced LVEF with ATTR-CM Arm:\n7. ATTR-CM objectively confirmed and classified at any time prior to the enrollment in the study, with monoclonal protein AL amyloidosis ruled out, according to American Heart Association (AHA) 2020 criteria\n\n   Inclusion criteria in Control Subjects:\n8. No diagnosis of HF or cardiomyopathy according to the universal definition of Heart Failure\n9. No diagnosis of Transthyretin amyloid cardiomyopathy (ATTR-CM) or Amyloid light-chain (AL) amyloidosis\n\nExclusion Criteria:\n\nExclusion criteria common to the three arms:\n\n1. Pregnant OR pre-menopausal woman\n2. Vulnerable patients\n3. Acute Coronary Syndrome within 30 days\n4. Heart rate greater than 130 beats\u002Fminute at the time of the measurements\n5. Atrial fibrillation or flutter at the time of SWV measurement (history of AF is authorized provided they patient is in sinus rhythm at the time of the measurements)\n6. Any clinically significant cardiac arrhythmia at the time of SWV measurement\n7. Poor echogenicity preventing accurate ultrasound measurements\n8. Patients with segmental wall motion abnormalities thought to be due to myocardial infarction.\n9. Severe mitral or aortic valve disease (regurgitation or stenosis) excluded if the cause is other than ATTR (e.g., prolapse, endocarditis, prosthetic valve.)\n10. Severe tricuspid valve disease (regurgitation or stenosis) excluded if the causes are other than ATTR.\n11. Distance from skin to IVS ≥ 8 cm\n12. Any prosthetic mechanical valve\n13. Patients with mechanical cardiac assist devices other than pacemakers or defibrillators\n14. Heart, lung, liver or kidney transplant history or expected in the next year\n15. Severe renal impairment with eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m² or end-stage renal disease or patient on dialysis.\n16. Presence of any competing life-threatening risk over the next 12 months\n17. Complicated uncontrolled diabetes mellitus HbA1c ≥9% with target organ damage.\n18. Uncontrolled and persistent high-blood pressure with diastolic pressure \\> 100 mmHg or systolic pressure \\> 160 mmHg at the time of the measurement.\n19. Acute decompensated state such as volume overload, etc. in the opinion of the study investigator\n20. Skin abnormalities, infections, or open wounds at the site of the SVW measurement\n21. Liver disease, at least moderate\n\n    Exclusion criteria in both the HF with non-reduced LVEF with or without ATTR-CM Arms:\n22. Known inherited cardiomyopathy, infiltrative cardiomyopathy (other than ATTR-CM for the study arm for ATTR-CM), cardiomyopathy from muscular dystrophies, cardiomyopathy with reversible causes (e.g., stress cardiomyopathy), hypertrophic cardiomyopathy or known pericardial constriction\n23. History of treatment for ATTR-CM with Transthyretin (TTR) depleters\n\n    Exclusion criteria Specific to Control Subjects:\n24. Any diagnosis of cardiomyopathy or HF, whatever the cause46\n25. LVH based on LV mass index female \\>95 g\u002Fm², in male ≥115 g\u002Fm² OR IVS thickness ≥12 mm unless thought to be due to athlete's heart","60 Years",{"count":263,"type":22},150,"The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and in control subjects without heart failure or cardiomyopathy.\n\nThe main question it aims to answer is:\n\n• Can SWV be used to measure myocardial and liver stiffness in the study's target populations? Researchers will compare patients with ATTR-CM, patients without ATTR-CM, and a control group to determine the distributions of SWV in each population.\n\nParticipants will:\n\n* Have a standard cardiology assessment, including a physical exam, blood work, and an echocardiogram.\n* Undergo an investigational assessment with the eMyosound LYRA device to measure SWV in their myocardium and liver.\n* Have the investigational assessment repeated by a second observer to assess measurement reliability.",[266,267,268,30,28],"HFpEF - Heart Failure With Preserved Ejection Fraction","HFmrEF","ATTR-CM (Transthyretin Amyloid Cardiomyopathy)",[270,271,257,159,28,272],"Shear Wave Velocity","non-invasive ultrasound elastography","ATTR-CM","2025-10-16",{"date":275,"type":41},"2025-10-20",{"date":277,"type":41},"2025-09-16",{"date":279,"type":22},"2026-07",{"name":281,"class":282},"eMyosound SAS","INDUSTRY",3,{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":17,"minAge":292,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":73},"100411941","postnatal-steroids-effects-on-cardiac-function-in-extremely-preterm-100411941","NCT04644094","Postnatal Steroids Effects on Cardiac Function in Extremely Preterm","\"Surveillance of Postnatal Steroids Effects on Cardiac Function in Extremely Preterm Infants With Evolving BPD: the SPEC Study.\"","SPEC","Inclusion Criteria:\n\n* \\\u003C 29 weeks of gestational age at birth admitted at the McGill University Children Hospital's neonatal intensive care unit\n* To be initiated on dexamethasone therapy for treatment of significant lung disease as per medical team decision.\n\nExclusion Criteria:\n\n* Congenital heart disease (except: Atrial septum defect (ASD), Ventricular septum defect (VSD)\n* Major congenital anomalies\u002Fgenetic disorder (Trisomy 13, 18, 21)\n* Congenital severe lung or airway malformation (Trachea-esophageal fistula, congenital pulmonary airway malformation, congenital diaphragmatic hernia)\n* Twin-twin transfusion syndrome","1 Minute",{"count":294,"type":22},21,"Hypothesis\u002FStudy question\n\nIn infants born at less than 29 weeks of estimated gestational age, what are the effects of dexamethasone use on cardiac structure\u002Fperformance and lung water content?\n\nStudy objectives\n\nTo measure effects before and after dexamethasone administration on cardiac structure\u002Fperformance will be evaluated by using the M-mode technique (Devereux method (25-27) and lung water content will be specifically determined by the degree of water retention in premature lungs assessed by lung ultrasound at the pre specified time points.\n\nMethodology \u002F Study design\n\nSingle center, prospective observational cohort study planning to enroll eligible patients over a period of 12 months",[30],[298,299,300,301,302,303],"Lung ultrasound","Echocardiography","Heart rate variability","Left ventricular hypertrophy","Ductus arteriosus","Dexamethasone","2025-06-12",{"date":306,"type":41},"2025-06-17",{"date":308,"type":41},"2021-06-15",{"date":310,"type":22},"2026-06",{"name":312,"class":48},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":321,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":335,"locationsCount":73},"100469071","sodium-lowering-vascular-effects-trial-100469071","NCT05388032","Sodium Lowering Vascular Effects Trial","A Mechanistic Trial of Dietary Sodium Reduction on Vascular Structure and Function","SOLVE","Inclusion Criteria:\n\n* Men or women aged ≥40 years. Individuals \\\u003C40 years are at a low risk for clinical and subclinical CVD\n* Elevated BP or hypertension (systolic BP ≥120 mmHg and diastolic BP ≥80 mmHg with or without use of antihypertensive medications)\n\nExclusion Criteria:\n\n* Glomerular filtration rate (eGFR) \\\u003C30 or end-stage renal disease (kidney transplant or chronic dialysis)\n* History of cardiovascular disease\n* Shift worker or regularly work at night\n* Cancer requiring chemotherapy or radiation treatment in the previous two years\n* Current pregnancy or breastfeeding or plans to become pregnant during the study\n* Consumption of ≥21 alcoholic drinks\u002Fweek\n* Current participation in another lifestyle intervention or drug trial\n* Current residence or planned residence that makes it difficult to meet trial requirements\n* Other concerns regarding ability to meet trial requirements (at the discretion of the study coordinator)","40 Years",{"count":323,"type":22},256,[25],"The proposed mechanistic trial will test the effect of dietary sodium reduction on cardiac and vascular structure and function in those with elevated blood pressure or hypertension. Findings from this study will fill the knowledge gap on the underlying mechanisms of dietary sodium intake on cardiovascular disease risk in addition to blood pressure and could provide further evidence on sodium reduction for the prevention of cardiovascular disease.",[327,328,30,184],"Endothelial Dysfunction","Vascular Stiffness","2024-11-20",{"date":331,"type":41},"2024-11-22",{"date":333,"type":41},"2023-01-25",{"date":250,"type":22},{"name":336,"class":48},"Tulane University",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":128,"sex":17,"minAge":343,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":73},"100260482","response-of-the-myocardium-to-hypertrophic-conditions-in-the-adult-population-100260482","NCT02670031","Response of the Myocardium to Hypertrophic Conditions in the Adult Population","Inclusion Criteria:\n\n1. 21 years and over\n2. Physician diagnosed essential hypertension, on at least 1 medication for blood pressure control\n3. Newly diagnosed hypertension: systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) on at least 2 office visits (Weber 2013) and not started on any anti hypertensive medications at time of ambulatory blood pressure monitoring\n4. Resistant hypertension: persistent systolic blood pressure 140mmHg or greater (diastolic blood pressure 90mmHg or greater) despite on at least 3 anti-hypertensive medications (Jennings 2013; Weber 2013)\n\nExclusion Criteria:\n\n1. Known secondary hypertension: renal causes (renal artery stenosis, chronic renal failure); endocrine causes (aldosterone excess, pheochromocytoma, cushing's syndrome, hyperthyroidism); cardiac causes (coarctation of the aorta)\n2. Contraindications to cardiovascular magnetic resonance: implantable devices, cerebral aneurysm clips, cochlear implants, renal impairment (GRF \\\u003C30ml\u002Fmin\u002F1.73m2), claustrophobia and women who are pregnant or breast-feeding\n3. Limited life expectancy\n4. On-going unstable medical conditions: hypertensive crisis, acute coronary syndromes or acute heart failure\n5. History of coronary artery disease, ischemic heart disease\n6. History of transient ischemic attacks or cerebrovascular events\n7. History of atrial fibrillation\n8. History of heart failure","21 Years","99 Years",{"count":346,"type":22},2000,"Hypertension and aortic stenosis are the two leading conditions that cause thickening of the heart muscles (left ventricular hypertrophy). Left ventricular hypertrophy is initially adaptive to maintain optimal heart function. Ultimately, heart failure occurs as a result of progressive muscle cell death and scarring (myocardial fibrosis). Dedicated techniques using cardiovascular magnetic resonance imaging (MRI) and novel high-sensitivity cardiac troponin blood assays are potential markers to detect myocardial fibrosis. Although hypertension-related heart disease is very common in Singapore, the significance of myocardial fibrosis is not well understood. In this study, the significance of myocardial fibrosis in 2000 patients with hypertension would be investigated. This will be the largest study using state-of-the-art MRI to examine the importance of myocardial fibrosis in hypertensive heart disease. 1000 participants, with at least 1 year follow-up, will be invited for a repeat assessment.",[30,62,349],"Myocardial Fibrosis",[351,62,30,349,352],"Hypertensive Heart Disease","Cardiovascular Magnetic Resonance Imaging","2023-07-31",{"date":355,"type":41},"2023-08-02",{"date":357,"type":4},"2016-01",{"date":359,"type":22},"2031-09",{"name":361,"class":48},"National Heart Centre Singapore",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":371,"conditions":372,"keywords":376,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":73},"100511691","etiological-diagnosis-of-cardiac-diseases-based-on-echocardiographic-images-and-clinical-data-100511691","NCT05942729","Etiological DiagnOsis of caRdiac Diseases Based on echoCardiograpHIc Images and Clinical Data.","ORCHID","Inclusion Criteria:\n\n* Patients with transthoracic echocardiography with satisfactory image quality (sufficient echogenicity)\n\nExclusion Criteria:\n\n* Minor patients\n* Patients under curatorship or guardianship",{"count":370,"type":22},1000,"Research hypothesis - Recent studies have shown that high-dimensional descriptors of the cardiac function can be efficiently exploited to characterize targeted pathologies. In this project, the investigators hypothesize that echocardiograms possess a wealth of information that is currently under-exploited and that, combined with relevant patient data, will allow the development of robust and accurate digital tools for etiological diagnosis.\n\nObjectives - Based on key advances recently obtained in image analysis, notably by members of the consortium, the objective of this project is to develop rigorous and explainable cardiac disease prediction models from echocardiography based on the transformer paradigm (AI). The strength of this study lies in the development of a strong AI framework to model the complex interactions between high-quality image-based measurements extracted from echocardiograms and relevant patient data to automatically predict etiological diagnosis of cardiac diseases",[373,374,375,30],"Hypertension Arterial","Hypokinetic","Cardiomyopathies",[62,377,378,379,380,381,301],"HTN","Arterial Hypertension","Artificial Intelligence","AI","Cardiac remodelling","2023-07-12",{"date":384,"type":41},"2023-07-13",{"date":386,"type":41},"2023-01-01",{"date":388,"type":22},"2027-01-01",{"name":390,"class":48},"Hospices Civils de Lyon"]